Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "Biologics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Biologics was estimated at US$421.1 Billion in 2023 and is projected to reach US$732.4 Billion by 2030, growing at a CAGR of 8.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Biologics, or biological drugs, have emerged as a revolutionary category of therapeutics, transforming the treatment landscape for chronic and complex diseases. These large, complex molecules are derived from living cells and are engineered to target specific components of human biology, making them highly effective for conditions like cancer, autoimmune disorders, and rare genetic diseases.
As more diseases are linked to genetic or molecular causes, biologics are taking center stage in the treatment of previously untreatable conditions, offering unprecedented precision and efficacy. The growing understanding of biological pathways in the human body, combined with advances in biotechnology, has made biologics a cornerstone of modern medicine.
What Is the Market Demand for Biologics Across Healthcare Sectors?
Biologics are widely used in various therapeutic areas, from oncology and immunology to endocrinology and infectious diseases. The increasing incidence of chronic diseases, such as diabetes, rheumatoid arthritis, and multiple sclerosis, has spurred demand for biologic therapies that offer improved outcomes over traditional small-molecule drugs.
In oncology, biologics such as immunotherapies and targeted therapies have significantly improved survival rates and reduced relapse. With aging populations and the rise in autoimmune diseases, the need for long-term, effective biologic treatments is expanding. The pharmaceutical sector is also seeing a surge in R&D investment, with major companies focusing on the development of novel biologics that address unmet medical needs, particularly for rare and orphan diseases.
The growth in the biologics market is driven by several factors, including advancements in biotechnological research, the increasing prevalence of chronic and autoimmune diseases, and the growing adoption of personalized medicine. Rising demand for targeted therapies that minimize side effects while maximizing treatment efficacy is also fueling the market. Furthermore, biosimilar approvals in regions like Europe and the U.S.
are expanding access to biologic therapies at lower costs, while technological innovations in biomanufacturing are streamlining production processes. The expanding application of biologics in oncology, immunology, and rare diseases, coupled with favorable regulatory environments, is expected to sustain the strong growth trajectory of the biologics market.
How Are Technological Advancements Reshaping the Biologics Landscape?
Biologics are benefiting from cutting-edge advancements in biotechnology, particularly in gene editing technologies like CRISPR and developments in monoclonal antibodies and cell-based therapies. Innovations such as CAR-T therapy, which uses a patient's immune cells to fight cancer, are pushing the boundaries of what biologics can achieve.
Furthermore, advancements in biomanufacturing techniques, including continuous manufacturing and single-use technologies, are helping scale biologics production while reducing costs. These technologies are also enabling greater control over product consistency and quality, which is crucial for the commercial viability of biologics. Additionally, the rise of biosimilars is allowing more patients access to affordable biologic therapies, accelerating their market penetration globally.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players in the Global Biologics Market such as AbbVie, Inc., Amgen, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Recombinant Therapeutic Proteins segment, which is expected to reach US$271.3 Billion by 2030 with a CAGR of a 8.8%. The Blood & Blood Components segment is also set to grow at 7.5% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $116.2 Billion in 2023, and China, forecasted to grow at an impressive 7.6% CAGR to reach $111.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 293 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $421.1 Billion |
| Forecasted Market Value (USD) by 2030 | $732.4 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of COVID-19 and a Looming Global Recession
- Biologics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
- Increasing Use of Biologics in Treating Chronic and Life-Threatening Conditions
- Technological Innovations in Monoclonal Antibodies and Gene Therapies
- Growing Demand for Biologics in Immunology, Oncology, and Rare Diseases
- Expansion of Precision Medicine Driving Demand for Biologics
- Rising Focus on Biosimilars to Improve Market Accessibility
- Regulatory Pathways Streamlining Biologics Approval and Market Entry
- Advances in Biomanufacturing Processes Enhancing Production Efficiency
- Increasing Adoption of Biologics in Pediatric and Geriatric Patient Populations
- Impact of Emerging Markets on Biologics Demand and Distribution
- Collaborations and Partnerships Fueling Biologics Development and Commercialization
FOCUS ON SELECT PLAYERS:Some of the 243 companies featured in this report include
- AbbVie, Inc.
- Amgen, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Janssen Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Pfizer, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/wxjro7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
